A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects With Early Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs JNJ 54861911 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Janssen Research & Development; Janssen-Cilag
- 07 Jun 2017 Biomarkers information updated
- 13 Jul 2016 This trial was completed in Netherlands, according to European Clinical Trials Database.
- 06 Jul 2016 Status changed from active, no longer recruiting to completed.